摘要
【摘要】 目的 分析莫西沙星联合抗结核药物治疗难治性结核性膜炎的临床疗效。方法 选取我市定点医院 56例难治性结核性脑膜炎患者作为研究对象， 随机分为联合组和对照组， 每组 28例。对照组采用抗结核药物进行治疗， 联合组在对照组的基础上加用莫西沙星进行治疗。比较两组治疗前、治疗后 6个月脑脊液指标以及发热时间、昏迷时间和住院时间。结果 与对照组比较， 联合组治疗后脑脊液中氯化物、葡萄糖含量均显著增高， 压力、蛋白质以及白细胞计数均显著降低（ P<0.05）；联合组发热时间、昏迷时间较对照组明显降低（ P<0.05）；联合组住院时间为（ 28.16±5.42） d， 低于对照组的（ 34.09±5.77） d（ P<0.05）。结论 莫西沙星联合抗结核药物治疗难治性结核性脑膜炎可以明显的改善脑脊液指标， 较快的减轻患者临床症状， 缩短住院时间， 具有推广的临床价值。
【关键词】 莫西沙星；抗结核药物；难治性结核性脑膜炎；临床疗效
[Abstract] Objective To analyze the clinical effect of moxifloxacin combined with antituberculous drugs in the treatment of refractory tuberculous membranositis. Methods 56 patients with refractory tuberculous meningitis were randomly divided into two groups, 28 in each group. The control group was treated with antituberculosis drugs, and the combined group was treated with moxifloxacin on the basis of the control group. The CSF indexes, fever time, coma time and hospitalization time of the two groups before and 6 months after treatment were compared. Results compared with the control group, the content of chloride and glucose in cerebrospinal fluid of the combined group was significantly increased, the pressure, protein and leukocyte count were significantly reduced (P < 0.05); the fever time and coma time of the combined group were significantly reduced (P < 0.05); the hospitalization time of the combined group was (28.16 ± 5.42) days, lower than that of the control group (34.09 ± 5.77) days (P < 0.05). Conclusion moxifloxacin combined with antituberculous drugs in the treatment of refractory tuberculous meningitis can significantly improve the cerebrospinal fluid index, quickly reduce the clinical symptoms of patients, shorten the length of stay, and have clinical value of promotion.
出版日期
2020年08月19日（中国期刊网平台首次上网日期，不代表论文的发表时间）
